Close Menu

Oxford Immunotec

Rapid Biosensor Systems said its point-of-care pre-production breath system has achieved high performance during TB field testing in Ethiopia and India.

Other big gainers last month included Accelerate Diagnostics and Natera, and share prices of 23 of the 27 companies in the index increased month over month.

The anticipated shortage for clinics comes at a time when more clinicians are already switching to lab-based IGRA testing, diagnostic industry executives said.

Oxford Immunotec said that it expects the report to further the trend toward interferon-gamma release assay adoption for healthcare personnel screening.

The company logged total Q1 revenues of $14.8 million, above its previous guidance of a revenue range of $13.4 million to $14.1 million.

Revenues included sales to the former US lab business and revenue from T-SPOT.TB tests sold to Quest after Nov. 6 as part of a long-term supply agreement.

The researchers also determined that the two most widely used IGRAs used for diagnosing the disease in developed countries are not accurate for active TB.

Among the updates provided Wednesday, Quidel's CEO noted the firm's growing presence in point-of-care markets, while PerkinElmer discussed plans for its Vanadis test.


The company also reaffirmed fiscal fourth quarter growth expectations including double-digit growth in the US for its TB testing products.

The reagent kit is designed to simplify workflow, improve throughput, and reduce hands-on time and labor costs in performing the T-Spot.TB test.

Pages